TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia |
Bahari, Gholamreza
(Cellular and Molecular Research Center, Zahedan University of Medical Sciences)
Hashemi, Mohammad (Cellular and Molecular Research Center, Zahedan University of Medical Sciences) Naderi, Majid (Genetics of Non Communicable Disease Research Center, Zahedan University of Medical Sciences) Taheri, Mohsen (Genetics of Non Communicable Disease Research Center, Zahedan University of Medical Sciences) |
1 | Li L, Li C, Mao H, et al (2016). Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci Rep, 6, 26591. DOI |
2 | Lorsbach RB, Moore J, Mathew S, et al (2003). TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia, 17, 637-41. DOI |
3 | Ma Y, Sui Y, Wang L, et al (2014). Effect of GSTM1 null genotype on risk of childhood acute leukemia: a metaanalysis. Tumour Biol, 35, 397-402. DOI |
4 | Makishima H, Jankowska AM, McDevitt MA, et al (2011). CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood, 117, 198-206. DOI |
5 | Abdel-Wahab O, Manshouri T, Patel J, et al (2010). Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res, 70, 447-52. DOI |
6 | Belson M, Kingsley B, Holmes A (2007). Risk factors for acute leukemia in children: a review. Environ Health Perspect, 115, 138-45. |
7 | Chim CS, Liang R, Kwong YL (2002). Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol, 20, 167-76. DOI |
8 | Chim CS, Wan TS, Fung TK, et al (2010). Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol, 63, 942-6. DOI |
9 | Delhommeau F, Dupont S, Della Valle V, et al (2009). Mutation in TET2 in myeloid cancers. N Engl J Med, 360, 2289-301. DOI |
10 | Eden T, Pieters R, Richards S, et al (2010). Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. Br J Haematol, 149, 722-33. DOI |
11 | Guo LM, Xi JS, Ma Y, et al (2014). ARID5B gene rs10821936 polymorphism is associated with childhood acute lymphoblastic leukemia: a meta-analysis based on 39,116 subjects. Tumour Biol, 35, 709-13. DOI |
12 | Hasani SS, Hashemi M, Eskandari-Nasab E, et al (2014). A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumour Biol, 35, 219-25. DOI |
13 | Jones PA, Baylin SB (2007). The epigenomics of cancer. Cell, 128, 683-92. DOI |
14 | Hashemi M, Ebrahimi M, Amininia S, et al (2014a). Evaluation of osteoprotegerin gene polymorphisms and the risk of childhood acute lymphocytic leukemia in Zahedan Southeast Iran. Int J Hematol Oncol Stem Cell Res, 8, 39-44. |
15 | Hashemi M, Moazeni-Roodi AK, Fazaeli A, et al (2010). Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res, 9, 333-9. DOI |
16 | Hashemi M, Sheybani-Nasab M, Naderi M, et al (2014b). Association of functional polymorphism at the miR-502- binding site in the 3’ untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report. Tumour Biol, 35, 10375-9. DOI |
17 | Ito S, D’Alessio AC, Taranova OV, et al (2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature, 466, 1129-33. DOI |
18 | Jankowska AM, Szpurka H, Tiu RV, et al (2009). Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 113, 6403-10. DOI |
19 | Kaatsch P (2010). Epidemiology of childhood cancer. Cancer Treat Rev, 36, 277-85. DOI |
20 | Kang MY, Lee BB, Ji YI, et al (2008). Association of interindividual differences in p14ARF promoter methylation with single nucleotide polymorphism in primary colorectal cancer. Cancer, 112, 1699-707. DOI |
21 | Kim YH, Pierscianek D, Mittelbronn M, et al (2011). TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol, 64, 850-2. DOI |
22 | Kosmider O, Gelsi-Boyer V, Cheok M, et al (2009a). TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114, 3285-91. DOI |
23 | Kosmider O, Gelsi-Boyer V, Ciudad M, et al (2009b). TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 94, 1676-81. DOI |
24 | Musialik E, Bujko M, Wypych A, et al (2014). TET2 Promoter DNA methylation and expression analysis in pediatric B-cell Acute Lymphoblastic Leukemia. Hematol Rep, 6, 5333. |
25 | Nibourel O, Kosmider O, Cheok M, et al (2010). Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 116, 1132-5. DOI |
26 | Perez C, Martinez-Calle N, Martin-Subero JI, et al (2012). TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One, 7, 31605. DOI |
27 | Quivoron C, Couronne L, Della Valle V, et al (2011). TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell, 20, 25-38. DOI |
28 | Tefferi A, Pardanani A, Lim KH, et al (2009). TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia, 23, 905-11. DOI |
29 | Scopim-Ribeiro R, Machado-Neto JA, Campos Pde M, et al (2015). Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. Eur J Haematol, 94, 413-8. DOI |
30 | Tahiliani M, Koh KP, Shen Y, et al (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324, 930-5. DOI |